$MRNA 24 hours down 4.6%, current price 144.83. Funding rate -0.00005187, shorts are paying.
When geopolitical tensions rise, the normal logic is that biotech vaccine stocks should attract some safe-haven buying, but instead $MRNA led the decline. The market is voting with its feet and simply doesn’t buy that logic. Either panic is first hitting the more liquid names, or there is some negative factor affecting this business that we haven’t seen yet.
The funding rate is negative, which means short positioning is building and bearish consensus is strong. But the price is falling, so this is not the typical structure of a short squeeze; rather, shorts are steadily pressing. Open interest at 9364 isn’t high, and there’s no obvious liquidation wall from a long-short standoff, so there may still be room for further downside.
The strongest counterargument would be a new domestic U.S. signal of pandemic risk, which would instantly reverse the narrative. But there is no such news at the moment.
If geopolitical tension continues and $MRNA keeps weakening, longs that were originally based on the safe-haven logic will be forced to cut positions, accelerating the decline.
My move: try shorting around 145 at the current price, with a stop loss at 146.5. If the price breaks below 140, I will consider adding to the position. The condition under which this logic fails is simple: if $MRNA rises back above 146 and closes above that level, then I’m wrong, and I’ll admit it and exit.
Trading tag: #TradFi #链上美股 #MRNA
Where do you think this judgment is most likely to be wrong?
When geopolitical tensions rise, the normal logic is that biotech vaccine stocks should attract some safe-haven buying, but instead $MRNA led the decline. The market is voting with its feet and simply doesn’t buy that logic. Either panic is first hitting the more liquid names, or there is some negative factor affecting this business that we haven’t seen yet.
The funding rate is negative, which means short positioning is building and bearish consensus is strong. But the price is falling, so this is not the typical structure of a short squeeze; rather, shorts are steadily pressing. Open interest at 9364 isn’t high, and there’s no obvious liquidation wall from a long-short standoff, so there may still be room for further downside.
The strongest counterargument would be a new domestic U.S. signal of pandemic risk, which would instantly reverse the narrative. But there is no such news at the moment.
If geopolitical tension continues and $MRNA keeps weakening, longs that were originally based on the safe-haven logic will be forced to cut positions, accelerating the decline.
My move: try shorting around 145 at the current price, with a stop loss at 146.5. If the price breaks below 140, I will consider adding to the position. The condition under which this logic fails is simple: if $MRNA rises back above 146 and closes above that level, then I’m wrong, and I’ll admit it and exit.
Trading tag: #TradFi #链上美股 #MRNA
Where do you think this judgment is most likely to be wrong?